Low SAFB levels are associated with worse outcome in breast cancer patients

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 503-509

  Hammerich Hille, Stephanie ^a   Bardout, Valerie J ^b   Hilsenbeck, Susan G ^a   Osborne, C Kent ^a   Oesterreich, Steffi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Breast cancer; Estrogen receptor; Predictive factor; Prognostic factor; SAFB; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PROTEIN; PROTEIN ANTIBODY; PROTEIN BCL 2; SAFB1 PROTEIN; SAFB2 PROTEIN; SCAFFOLD ATTACHMENT FACTOR B; TAMOXIFEN; TUMOR EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC THERAPY;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOBLOTTING; KAPLAN-MEIERS ESTIMATE; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; NUCLEAR MATRIX-ASSOCIATED PROTEINS; PROGNOSIS; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77953020379     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0297-6     Document Type: Article

References (26)

1. Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15(2 Suppl 1): 20-25
2. Denegri M, Moralli D, Rocchi M et al (2002) Human chromosomes 9, 12, and 15 contain the nucleation sites of stress-induced nuclear bodies. Mol Biol Cell 13(6): 2069-2079. doi: 10.1091/ mbc.01-12-0569
3. Lee YB, Colley S, Norman M et al (2007) SAFB re-distribution marks steps of the apoptotic process. Exp Cell Res 313(18): 3914-3923. doi:10.1016/j.yexcr. 2007.06.023 (Pubitemid 47566378)
4. WeighardtF,CobianchiF,CartegniLetal(1999)AnovelhnRNPprotein(HAP/SAF-B) entersasubsetofhnRNPcomplexesandrelocatesinnucleargranulesinresponse-heatshock. JCellSci112(Pt10):1465-1476(Pubitemid29261309)
5. Oesterreich S, Zhang Q, Hopp T et al (2000) Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol 14(3): 369-381, doi:10.1210/me.14.3.369 (Pubitemid 32260529)
6. Debril MB, Dubuquoy L, Feige JN et al (2005) Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity. J Mol Endocrinol 35(3): 503-517. doi: 10.1677/jm.e.1.01856 (Pubitemid 43025575)
7. OsborneCK,BardouV,HoppTAetal(2003) RoleoftheestrogenreceptorcoactivatorAIBl(SRC-3)andHER-2/ neuintamoxifenresistanceinbreastcancer.JNatlCancerInst95(5):353- 361(Pubitemid36395255)
8. GiraultI,LereboursF,AmarirSetal(2003) Expressionanalysisofestrogenreceptoralphacoregulatorsinbreastcarcinoma: evidencethatNCOR1expressionispredictiveoftheresponse-tamoxifen.ClinCancerRes9(4) :1259-1266(Pubitemid36418375)
9. Hull DF III, Clark GM, Osborne CK et al (983) Multiple estrogen receptor assays in human breast cancer. Cancer Res 43(1): 413-416
10. Encarnacion CA, Ciocca DR, McGuire WL et al (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26(3): 237-246. doi: 10.1007/BF00665801 (Pubitemid 23304239)
11. Dressler LG, Seamer LC, Owens MA et al (1988) DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61420-427. doi: 10.1002/1097-0142(198802 01)61: 3<420::AID-CNCR2820610303>3.0.CO;2-0
12. Jiang S, Meyer R, Kang R et al (2006) Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol 20(2): 311-320. doi: 10.1210/me.2005-0100 (Pubitemid 43152506)
13. Miller BJ, Wang D, Krahe R et al (2003) Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am. J Hum. Genet 73(4): 748-767. doi: 10.1086/378522 (Pubitemid 37271880)
14. Oesterreich S, Allredl DC, Mohsin SK et al (2001) High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer 84(4):493-498. doi: 10.1054/bjoc.2000.1606
15. Townson SM, Sullivan T, Zhang Q et al (2000) HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res 6(9): 3788-3796
16. Townson SM, Dobrzycka KM, Lee AV et al (2003) SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor. J Biol Chem 278(22): 20059-20068. doi:10.1074/ jbc.M212988200
17. Townson SM, Kang K, Lee AV et al (2004) Structure-function analysis of the estrogen receptor alpha corepressor scaffold attachment factor-B1: identification of a potent transcriptional repression domain. J Biol Chem. 279(25): 26074-26081, doi: 10.1074/jbc.M31.3726200
18. Bergman A, Abel F, Behboudi A et al (2008) No germline mutations in supposed tumour suppressor genes SAFB1 and SAFB2 in familial breast cancer with linkage to 19p. BMC Med Genet 9(1): 108. doi: 10.1186/1471-2350-9-108
19. Lee JY, Dong SM, Kim HS et al (1998) A distinct region of chromosome 19p13.3 associated with the sporadic form of adenoma malignum of the uterine cervix. Cancer Res 58: 1140-1143
20. Sobottka SB, Haase M, Fitze G et al (2000) Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol 49(3): 187-195. doi: 10.1023/A:1006442024874
21. Adachi N, Lieber MR (2002) Bidirectional gene organization: a common architectural feature of the human genome. Cell 109(7): 807-809. doi: 10.1016/S0092-8674(02)00758-4
22. Yang MQ, Koehly LM, Elnitski LL (2007) Comprehensive annotation of bidirectional promoters identifies co-regulation among breast and ovarian cancer genes. PLOS Comput Biol 3(4): e72. doi: 10.1371/journal.pcbi.0030072
23. Yang MQ, Elnitski LL (2008) Diversity of core promoter elements comprising human bidirectional promoters. BMC Genomics 9(Suppl 2): S3
24. Chan CM, Lykkesfeldt AE, Parker MG et al (1999) Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifenresistant breast cancer. Clin Cancer Res 5(11): 3460-3467
25. Fleming FJ, Myers E, Kelly G (2004) Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1. J Clin Pathol 57(10): 1069-1074. doi:10.1136/jcp.2004.01.6733
26. Myers E, Fleming FJ, Crotty TB (2004) Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrineresistant breast cancer. Br J Cancer 91(9): 1687-1693